BMS-owned patent for hepatitis B drug entecavir has remained at the
center-stage of patent disputes across many jurisdictions. In USA, TEVA
initiated a patent fight against BMS for
Entecavir patent and it was rejected on grounds of strong evidence
of non-obviousness.
So when in India, Natco Pharma filed a
rectification application for revocation of the patent of entecavir, the flaws
in the patent were bound to have impacted the judgement of Indian Patent Office
and the court. The end result, however, was far away from expectations.
Even before the court and the IPAB could reach
at a decision, the counsels of the involved parties appeared in the court
during the hearing in Chennai and informed the Board that they have settled the
issue. The terms of settlement remains undisclosed as the parties requested the
court and the IPAB to not disclose it to any third party.
BMS owns patent for entecavir, filed on July 2, 2002 and
published on January 25, 2008.
Post by Sagacious IP
No comments:
Post a Comment